Product Description
Amitriptylinoxide is an organic tricyclic compound. Amitriptylinoxide has been used in trials studying Major Depression. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Amitriptylinoxide)
Mechanisms of Action: NET Blocker, SERT Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: HolsboerMaschmeyer NeuroChemie
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Depressive Disorder, Major|Bipolar Disorder|Psychotic Disorders
Phase 3: Schizophrenia|Depressive Disorder|Dementia|Tic Disorders|Psychophysiologic Disorders
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02374567 |
GAP | P3 |
Terminated |
Psychophysiologic Disorders|Tic Disorders|Dementia|Schizophrenia|Depressive Disorder |
2017-06-28 |
2024-10-16 |
Primary Endpoints|Treatments |
|
NCT02237937 |
NCT02237937 | P4 |
Unknown status |
Depressive Disorder, Major |
2014-12-01 |
2019-03-20 |
||
2011-003190-29 |
ABCB1 Clinical Study | P4 |
Active, not recruiting |
Depressive Disorder, Major|Psychotic Disorders|Bipolar Disorder |
2014-01-30 |
2022-03-13 |
Treatments |